(VVOS) Vivos Therapeutics, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VVOS) Vivos Therapeutics, Inc. Complete Analysis Pack
Explore the Complete Growth Strategy Behind the Preview
This Vivos Therapeutics, Inc. Ansoff Matrix Analysis maps the company’s growth options—market penetration, market development, product development, and diversification—and explains how its products (oral appliance therapy for sleep-disordered breathing) fit each quadrant. The page contains a real preview/sample of the analysis so you can judge style and substance; purchase the full version to receive the complete ready-to-use report.
Market Penetration
U.S. and Canada general-dentist channel deepening
Vivos Therapeutics can deepen penetration by lifting adoption within its existing U.S. and Canada general-dentist base, not by changing the core Vivos System. The U.S. has about 200,000 dentists and Canada about 25,000, so even small gains in repeat use and new-office conversion can move revenue fast. Its licensed-medical-professional model supports this, since the same channel can drive more placements with lower incremental go-to-market cost.
Adult OSA and snoring case conversion
Vivos Therapeutics, Inc. can expand adult OSA and snoring case conversion by pushing its current Vivos System into a huge unmet market: about 1 billion adults worldwide are estimated to have obstructive sleep apnea. The non-invasive, non-surgical, drug-free model helps dentists turn more screenings into treatment, lifting penetration in the installed base.
VivoScore screening-to-treatment funnel
VivoScore can widen Vivos Therapeutics, Inc.'s funnel by turning more screening leads into Vivos System therapy, especially in a U.S. OSA market where about 80% of moderate-to-severe cases remain undiagnosed. The program already pairs comprehensive screening with home sleep tests for adults and children, so it lowers friction from first contact to treatment. Better screening-to-treatment conversion should lift sales inside the current market without needing new categories.
Dentofacial abnormality treatment emphasis
Vivos Therapeutics, Inc. should frame the Vivos System more tightly for adults with dentofacial abnormalities, so the message stays aligned with its OSA and snoring focus and is easier for practitioners to adopt. Adult sleep apnea is common: about 30 million U.S. adults have it, and nearly 80% of moderate to severe cases remain undiagnosed, which supports a clearer entry point.
- Focus on adult dentofacial cases
- Match OSA and snoring positioning
- Reduce confusion for dentists
- Use the 30 million market signal
Licensed-professional education and activation
Vivos Therapeutics, Inc. can grow faster by getting more use from the licensed dentists it already has, not just adding new ones. The direct lever is activation: in 2025, every extra practice using the multidisciplinary therapy model more often should raise patient starts without a big jump in fixed costs.
General dentists sit at the center of the channel, so education that shows how airway, sleep, and dental care work together can lift case flow. If even a small share of current providers moves from occasional use to routine use, market penetration improves with the same sales base.
- Focus on current general dentists
- Teach the multidisciplinary care model
- Raise case frequency per provider
- Use activation as the main lever
Vivos Can Grow Faster by Activating Its 225,000-Dentist Channel
Vivos Therapeutics, Inc. can drive market penetration by getting more use from its current U.S. and Canada dentist base and converting more of the estimated 30 million U.S. adults with sleep apnea. With about 80% of moderate-to-severe cases still undiagnosed, tighter screening, VivoScore, and routine provider activation can raise starts without changing the core Vivos System.
| Lever | Data point |
|---|---|
| Current channel | 225,000 dentists |
| OSA gap | 80% undiagnosed |
| Market pool | 30M U.S. adults |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix view of Vivos Therapeutics, Inc.’s growth options across existing and new products and markets
Editable Excel File
Provides a clear Vivos Therapeutics Ansoff Matrix snapshot to quickly align growth strategy across existing and new markets.
Reference Sources
Cites primary regulatory filings, clinical data, investor presentations, and peer-reviewed studies to validate Ansoff Matrix growth paths for Vivos Therapeutics.
Market Development
Broader licensed-provider reach beyond general dentists
Vivos Therapeutics can extend the Vivos System beyond general dentists to sleep physicians, ENTs, and other licensed providers who treat sleep-disordered breathing. That is market development: the therapy stays the same, but the buyer channel widens. With about 30 million U.S. adults affected by obstructive sleep apnea, even modest provider adoption can open a much larger patient pool.
Adjacency into sleep-care referral networks
Vivos Therapeutics can win new sleep-care referral networks by partnering with practices that co-manage OSA and snoring patients, where demand for non-invasive options stays high. Its appliance-based model fits referrals from dentists, ENTs, and sleep clinics that want alternatives to drugs or surgery. That gives Vivos Therapeutics a low-friction way to place existing products into a broader care path.
Children and family screening expansion
Vivos Therapeutics, Inc. can use VivoScore’s adult and child screening to tap family care pathways, not just adult-only sleep workflows. Pediatric obstructive sleep apnea affects about 1% to 6% of children, so the child-testing feature widens the addressable market without changing the core screening product. That makes the same tool useful for whole-family referrals and earlier capture.
Geographic expansion within North America
Vivos Therapeutics, Inc. can drive market development by widening coverage across more local practice markets in the U.S. and Canada, rather than changing the product set. The play is reach, not reinvention: more orthodontists, dentists, and sleep-focused clinics in the same two-country base. In FY2025, this kind of geographic pull matters more than product launch risk because the company already has a North American channel.
- Expand practice reach within U.S. and Canada.
- Use the same product line.
- Target more local clinics, not new products.
OSA and snoring awareness outside the core dental base
OSA and snoring awareness outside the core dental base can widen Vivos Therapeutics, Inc.’s addressable market, since the Vivos System already fits treatable sleep-disordered breathing demand. Nearly 1 billion adults worldwide are estimated to have obstructive sleep apnea, so even modest awareness gains can open new patient and practice channels beyond dental adopters.
- Expand into non-dental referral paths
- Use existing OSA and snoring positioning
- Target awareness-driven demand pockets
Vivos Expands Reach Across Sleep Apnea Referral Networks
Vivos Therapeutics, Inc. is pursuing market development by pushing the same Vivos System into more referral paths, especially sleep physicians, ENTs, and broader clinic networks. That fits a large base: about 30 million U.S. adults have obstructive sleep apnea, and nearly 1 billion adults worldwide are estimated to be affected. Child screening via VivoScore also widens access, since pediatric OSA affects about 1% to 6% of children.
| Market development lever | Relevant number |
|---|---|
| U.S. adult OSA pool | About 30 million |
| Global adult OSA pool | Nearly 1 billion |
| Pediatric OSA rate | 1% to 6% |
What You See Is What You Get
Vivos Therapeutics, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. It covers Vivos Therapeutics’ market penetration, product development, market development, and diversification strategies with actionable insights. The full, editable report is available immediately after checkout.
Product Development
Vivos System therapy refinements
Vivos Therapeutics, Inc. should keep refining the Vivos System for adults with dentofacial abnormalities, obstructive sleep apnea, and snoring, since product development here means better therapy, not a new market. The priority is to preserve its non-invasive, non-surgical, drug-free profile while improving fit, comfort, and adherence.
That matters because sleep apnea affects about 39 million adults in the U.S., and snoring remains a large adjacent need. If Vivos can lift completion and satisfaction in this base, it can deepen repeat use without changing its core Ansoff path.
Near-term refinements should focus on outcomes, ease of use, and clinical workflow, since those are the levers that can move adoption.
VivoScore Program expansion
VivoScore expansion is a product development move that deepens Vivos Therapeutics, Inc.'s screening and home sleep test service as a complement to therapy. Since the program already serves adults and children, adding workflow features can widen use across more patient paths and strengthen the diagnostic-to-therapy funnel in a market where obstructive sleep apnea affects millions of people. That should support higher conversion from screening to treatment and more repeat clinical use.
Integrated screening and treatment bundles
Vivos Therapeutics, Inc. can bundle VivoScore with the Vivos System to create one care path from screening to treatment. That fits a market where obstructive sleep apnea affects about 25 million U.S. adults, so providers want fewer handoffs and faster starts. Product development should focus on one workflow, simpler ordering, and easier follow-up for clinicians.
Practice-support tools for licensed professionals
Vivos Therapeutics, Inc. should add practice-support tools that let dentists and other licensed providers screen, manage, and track patients inside the same platform. This is product development in the Ansoff Matrix because it deepens use of the current offer, while reducing workflow friction that can slow provider adoption.
By embedding patient intake, case tracking, and follow-up tools, Vivos Therapeutics, Inc. can make the service more useful at the point of care and increase repeat use. In a model that depends on provider adoption, simpler workflows can matter more than new features alone.
Key focus: fewer clicks, clearer patient status, and better visibility across the treatment path. This supports stickier usage without changing the core market.
- Screen patients faster
- Track cases in one place
- Cut workflow friction
- Lift platform adoption
Child-friendly workflow enhancements
Vivos Therapeutics, Inc. can lift VivoScore adoption by tightening child screening and home sleep-test steps for pediatrics. Since children are already in scope, the upside is usability, faster clinic flow, and fewer setup errors, which can help more existing practices use the platform. Child-focused workflow fixes matter because pediatric sleep-disordered breathing is common and often missed.
- Simpler pediatric intake
- Cleaner home-test setup
- Better practice adoption
Vivos Focuses on Better Fit, Comfort, and Workflow
Product development for Vivos Therapeutics, Inc. means improving the Vivos System and VivoScore for existing adult and pediatric patients, not entering a new market. The focus is better fit, comfort, screening, and workflow so providers use the platform more often. With U.S. sleep apnea affecting about 39 million adults, even small gains in adherence and clinic flow can lift adoption.
| Item | Data |
|---|---|
| U.S. adults with OSA | 39 million |
| Focus | Fit, comfort, workflow |
Diversification
Pediatric airway-health solutions
Vivos Therapeutics, Inc. can widen from adult OSA and snoring into pediatric airway-health solutions, and VivoScore already gives it a child entry point. Pediatric sleep-disordered breathing affects about 1% to 5% of children, so a child-focused line could tap a real unmet need. That would shift Vivos Therapeutics, Inc. beyond its adult-centered treatment base.
Digital care coordination platform
Vivos Therapeutics can diversify by building a digital care coordination platform for screening, patient handoffs, and follow-up, adding a new product line next to its device and testing service. With obstructive sleep apnea affecting about 1 billion adults worldwide, this could widen reach across dental, medical, and telehealth providers. It also helps standardize care across geographies and keep patients in the workflow longer.
Adjunct diagnostic services
Vivos Therapeutics, Inc. can extend beyond screening and home sleep tests into adjunct diagnostic services, adding a new offer to its current sleep-care stack. With obstructive sleep apnea affecting about 1 billion adults worldwide, broader diagnostics can widen reach and catch more cases earlier.
That shift fits Ansoff Matrix diversification because it pairs a new service with a broader market, not just more of the same test. It can also lift per-patient revenue if Vivos bundles assessment, testing, and follow-up care.
Provider training and implementation services
Vivos Therapeutics, Inc. can add a separate revenue stream by packaging provider training, onboarding, and practice-implementation services for licensed professionals. That supports adoption beyond the core treatment system, especially in new clinics and specialties. The shift fits Ansoff diversification because the company sells a new service layer to a wider provider base, not just a device.
New service stream
Faster clinic onboarding
Broader provider adoption
International licensed-provider markets
International licensed-provider markets would be a true Diversification move for Vivos Therapeutics, Inc. because the company is still centered in the U.S. and Canada, so entering Europe, Latin America, or Asia would add a new customer base and new regulatory paths. If Vivos Therapeutics, Inc. pairs local distribution, training, and support with its licensed-provider model, it can spread revenue risk beyond North America.
- New geography, new demand pool
- Needs localized offers and support
- Moves from market development to diversification
- Can reduce North America concentration risk
Vivos Expands Beyond OSA Into Pediatric and Digital Care
Diversification for Vivos Therapeutics, Inc. means moving beyond adult OSA devices into new offers like pediatric airway care, digital care coordination, and provider services. That fits Ansoff because it adds new products and new users; OSA affects about 1 billion adults, while pediatric sleep-disordered breathing affects 1% to 5% of children.
| Move | Signal |
|---|---|
| Pediatric line | 1% to 5% children |
| Digital platform | New service layer |
| Provider training | New revenue stream |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.